BW 245C

Drug Profile

BW 245C

Latest Information Update: 16 Jan 1996

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiplatelets; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin D agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronary disorders; Thrombosis

Most Recent Events

  • 16 Jan 1996 Discontinued-I for Coronary disorders in United Kingdom (Unknown route)
  • 04 May 1995 Discontinued-I for Thrombosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top